Choreo LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,569 shares of the company’s stock, valued at approximately $1,227,000.
A number of other institutional investors have also added to or reduced their stakes in the company. Riverview Trust Co purchased a new position in IDEXX Laboratories in the 1st quarter worth $26,000. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories during the first quarter valued at approximately $26,000. Ridgewood Investments LLC purchased a new stake in IDEXX Laboratories in the second quarter worth $27,000. Institutional & Family Asset Management LLC bought a new stake in IDEXX Laboratories in the second quarter valued at $28,000. Finally, DSM Capital Partners LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at $33,000. Institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Price Performance
IDXX opened at $497.04 on Friday. The firm has a market cap of $41.05 billion, a PE ratio of 48.12, a P/E/G ratio of 4.02 and a beta of 1.33. The stock has a 50-day moving average price of $480.89 and a 200-day moving average price of $502.21. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. BTIG Research began coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, Piper Sandler decreased their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $582.25.
Check Out Our Latest Analysis on IDXX
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- What is the NASDAQ Stock Exchange?
- 3 Leveraged ETFs to Multiply Returns
- Why Invest in High-Yield Dividend Stocks?
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.